AI Analysis | Feedback

Here are a few analogies for Vicarious Surgical (RBOT):

• Intuitive Surgical (ISRG) for immersive robotic surgery.
• A 'surgeon-inside-the-patient' robotics company, like a more advanced Intuitive Surgical (ISRG).

AI Analysis | Feedback

• Vicarious System: A single-incision surgical robot designed to perform minimally invasive ventral hernia repair by virtually transporting surgeons inside the patient.

AI Analysis | Feedback

Major Customers of Vicarious Surgical (RBOT)

Vicarious Surgical Inc. (RBOT) develops and sells the Vicarious System, a single-incision surgical robot designed for minimally invasive surgery, specifically ventral hernia repair.

Given the nature of its product, a high-tech medical device and capital equipment, Vicarious Surgical primarily sells to other companies and institutions within the healthcare sector, rather than directly to individuals. For companies in the medical device industry, particularly those developing complex surgical systems, specific "major customers" are often not publicly disclosed by name in regulatory filings unless one customer accounts for a significant portion of revenue, which is uncommon for companies in the early commercialization phase of such specialized equipment. Therefore, specific customer company names and symbols are not available.

The primary categories of customers for Vicarious Surgical would include:

• Hospitals: Large acute care facilities that perform a high volume of surgical procedures and are early adopters of advanced medical technologies.
• Ambulatory Surgical Centers (ASCs): Outpatient facilities that focus on specific types of surgeries, including those for which robotic assistance could offer benefits.
• Integrated Delivery Networks (IDNs) / Healthcare Systems: Large organizations that own and operate multiple hospitals, clinics, and other healthcare facilities, potentially making system-wide purchasing decisions for new technologies.

AI Analysis | Feedback

AI Analysis | Feedback

Stephen From, Chief Executive Officer

Appointed CEO effective August 7, 2025, Mr. From brings over 20 years of leadership experience in the healthcare and financial industries. He most recently served as CEO of Aruna Bio, a biotech firm. Prior to that, he was Executive Chairman of Kiora Pharmaceuticals (formerly EyeGate Pharmaceuticals), where he oversaw an initial public offering and multiple acquisitions and licensing transactions. He also served as CFO of Centelion, a biotech subsidiary of Sanofi-Aventis, and worked in investment banking focusing on the life sciences sector.

Sarah Romano, Chief Financial Officer

Appointed CFO effective April 1, 2025, Ms. Romano has extensive experience in the healthcare sector, particularly with public companies, where she has led successful fundraising and mergers and acquisitions. Her previous roles include CFO of Entero Therapeutics, where she managed financial strategy and operations and raised significant funding, and CFO of Kiora Pharmaceuticals, where she secured over $50 million in funding and led M&A activities. She holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.

Adam Sachs, Co-Founder & President

Mr. Sachs co-founded Vicarious Surgical in 2014 with Sammy Khalifa and Dr. Barry Greene. He served as CEO until August 7, 2025, when he transitioned to President. An MIT engineering graduate, he previously worked at Apple in manufacturing. Vicarious Surgical has received investments from prominent technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, and Eric Schmidt's Innovation Endeavors.

Sammy Khalifa, Co-Founder & Chief Technology Officer

Mr. Khalifa co-founded Vicarious Surgical in 2014 alongside Adam Sachs and Dr. Barry Greene. He holds a B.S. in Mechanical Engineering from MIT. His prior experience includes working as a Product Design Engineer at Apple and a Biomedical Design Engineer at Hemedex.

Dr. Barry Greene, Co-Founder & Chief Medical Officer

Dr. Greene co-founded Vicarious Surgical in 2014 with Adam Sachs and Sammy Khalifa. He is a board-certified Bariatric and General Surgeon with over 25 years of experience performing advanced laparoscopic surgical procedures. He provided valuable insights into the development of the company's robotic technology based on his extensive surgical background.

AI Analysis | Feedback

Key Risks to Vicarious Surgical (RBOT)

1. Going Concern and Liquidity Crisis: Vicarious Surgical Inc. faces substantial doubt about its ability to continue as a going concern, with current financial resources anticipated to fund operations only through the second quarter of 2026. The company is a pre-revenue, development-stage entity that has not generated revenue from product sales and continues to incur significant losses, necessitating substantial additional funding to complete clinical trials, obtain market authorization, and commercialize its surgical system.
2. NYSE Delisting and OTC Transition: The company has been delisted from the New York Stock Exchange due to failing to maintain the minimum global market capitalization requirement, and its shares now trade on the OTCID market. This transition is expected to reduce share liquidity, limit access to capital markets, and may result in a loss of investor confidence and further declines in share price.
3. Regulatory Risks and Development Stage: As a development-stage company, Vicarious Surgical's success is contingent upon obtaining U.S. Food and Drug Administration (FDA) authorization for its Vicarious Surgical System. The company's business is subject to extensive regulatory requirements, and any delays, non-compliance, or failure to secure necessary approvals could materially impact its ability to commercialize its products. Furthermore, the company lacks experience in the sales and marketing of its system.

AI Analysis | Feedback

AI Analysis | Feedback

Vicarious Surgical Inc. (RBOT) is developing a single-incision surgical robot designed for minimally invasive abdominal procedures, with an initial focus on ventral hernia repair.

The company estimates that its robotic system can address a global market opportunity of 45 million abdominal procedures annually, which represents an addressable market of $150 billion.

AI Analysis | Feedback

Vicarious Surgical Inc. (RBOT) is a pre-commercial, development-stage company with no product revenue to date. Therefore, its future revenue growth over the next 2-3 years will be driven by critical milestones leading to the commercialization and adoption of its single-incision surgical robot system. Key drivers include:

1. Achieving Design Freeze and Readiness for Regulatory Submission: A primary driver for future revenue is the successful completion of the production-equivalent system, targeting design freeze by the end of 2026. This milestone is crucial for preparing the system for regulatory review and eventual commercialization.
2. Securing Regulatory Approval (FDA Clearance): Obtaining regulatory authorization from the U.S. Food and Drug Administration (FDA) is a prerequisite for Vicarious Surgical to market and sell its Vicarious System. The company had previously outlined plans for an FDA submission and first-in-human trials, although timelines have been adjusted.
3. Successful Commercial Launch and Initial Adoption: Once regulatory approval is secured, the commercial launch of the Vicarious Surgical System will be the direct driver of revenue. The company aims to redefine robotic surgery by expanding access to millions of procedures, particularly in areas like ventral hernia repair.
4. Market Penetration in Minimally Invasive Abdominal Procedures: Vicarious Surgical's unique single-port system is designed to provide open-like access and dexterity through a minimal incision, addressing a significant portion of abdominal procedures that are currently non-robotic. Successful penetration into this large, underserved market is expected to drive adoption and, consequently, revenue growth.
5. Technological Advancements and Product Enhancements: Continuous innovation, such as the development of disposables that allow for even smaller incision sizes (e.g., targeting 1.5 cm from the current 1.8 cm, with system capability as low as 1.2 cm), could enhance the product's appeal, improve patient outcomes, and differentiate it in the competitive surgical robotics market, fostering broader adoption.

AI Analysis | Feedback

Share Repurchases

Vicarious Surgical has not reported any share repurchases or authorized future share repurchase programs within the last 3-5 years.

Share Issuance

• In September 2021, Vicarious Surgical completed a business combination that generated approximately $220 million in gross proceeds.
• This included a $142 million Private Investment in Public Equity (PIPE) transaction.
• A 1-for-30 reverse stock split was executed in June 2024.

Inbound Investments

• The company received approximately $220 million in gross cash proceeds from a business combination in September 2021, intended to fund the development and commercialization of its surgical robot.
• This included a $142 million PIPE investment supported by strategic investors, including Bill Gates and Vinod Khosla's Khosla Ventures.

Outbound Investments

No information regarding outbound investments by Vicarious Surgical was found in the provided search results.

Capital Expenditures

• Vicarious Surgical reported $0 in capital expenditures during the second quarter of 2025.
• The primary focus of capital allocation has been on research and development for its surgical robotic system, with expenses totaling $33.6 million in 2025 and $40.2 million in 2024.
• The company anticipates a full-year 2026 cash burn of approximately $19 million.